GW Pharmaceuticals Plc GWPHV

Rupert Haynes

[Ineedmoneyxxx]

--As head of Global Marketing at GW Pharmaceuticals, Mr. Rupert Haynes oversaw the strategic development of the firms cannabinoid portfolio including numerous cannabinoid pipeline products across dozens of therapeutic areas, but primarily neurological, neurodegenerative and neuropsychological conditions. Mr. Haynes was also involved in the strategic planning & development of Epidiolex, an FDA-approved cannabidiol, for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome So he is the guy responsible for the development etc of the drug they just released which is the first cannabis based pharmacutical with FDA approval. Why would GW let him go to work for a competitor company?